Good morning. I am grateful to Dr Calderwood for attending with me, given all the other pressures on her diary. I am grateful, too, to the committee for inviting me to give evidence on the petition.
As you will be aware from my letter of 8 August, the Scottish health technologies group published its advice statement on the flash glucose monitoring device FreeStyle Libre on 13 July 2018. My letter stated that the national health service boards that had not yet included FreeStyle Libre in their local formularies were considering how to implement the advice to best effect. To update the committee, all NHS boards in Scotland have included FreeStyle Libre in their local formularies and are making it available on prescription. I expect all boards to make FreeStyle Libre available to patients in line with clinical guidelines and in a phased and controlled manner to ensure that appropriate education is delivered prior to initiation and in recognition of the challenges for the manufacturer in matching demand. That move will benefit many individuals across Scotland, and I hope that it will reassure the committee that the spirit of the petitioner’s concerns in relation to FreeStyle Libre has now been met.
At the committee’s meeting on 28 June last year, my officials clarified that FreeStyle Libre is not a continuous glucose monitor. As more clinical evidence becomes available, FreeStyle Libre is showing positive effects in improving quality of life by reducing the number of finger-prick tests that patients need to carry out to self-manage their diabetes. However, FreeStyle Libre is not suitable for some patients, particularly for those who have limited or no hypoglycaemic awareness. There is strong clinical evidence to demonstrate that CGMs have a positive impact for a small cohort of patients with frequent or severe hypoglycaemia and that they improve glycaemic control and reduce hypoglycaemic episodes and emergency hospital admissions. We will continue to provide NHS boards with additional funding specifically for continuous glucose monitors so that the boards will increase the number available to diabetes patients where that is clinically indicated.
As the committee will be aware, diabetes remains a clinical priority for the Scottish Government. I reassure members that I am committed to ensuring that our health service continues to deliver care and treatment of the highest quality.
I am of course happy to answer any questions that members may have.